$KRYS
Krystal Biotech, Inc.

2018 Q1 Form 10-K Financial Statement

#000156459018005252 Filed on March 12, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q4 2017
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $760.0K $410.0K $1.560M
YoY Change 406.67% 86.36% 290.0%
% of Gross Profit
Research & Development $1.520M $1.090M $3.208M
YoY Change 376.49% 172.5% 332.93%
% of Gross Profit
Depreciation & Amortization $18.00K $10.00K $23.00K
YoY Change 1700.0% 1050.0%
% of Gross Profit
Operating Expenses $2.277M $1.500M $4.772M
YoY Change 389.68% 141.94% 317.5%
Operating Profit -$2.277M -$4.772M
YoY Change 389.68% 317.5%
Interest Expense $130.0K $110.0K -$3.150M
YoY Change -533.33% -1200.0% 31400.0%
% of Operating Profit
Other Income/Expense, Net $127.0K -$3.148M
YoY Change -537.93% 44871.43%
Pretax Income -$2.150M -$1.390M -$7.920M
YoY Change 338.78% 120.63% 588.7%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.150M -$1.390M -$7.920M
YoY Change 335.22% 120.63% 588.7%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$208.5K -$132.1K -$768.2K
COMMON SHARES
Basic Shares Outstanding 10.31M 10.24M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q4 2017
SHORT-TERM ASSETS
Cash & Short-Term Investments $47.20M $49.60M $49.60M
YoY Change 2260.0% 2510.53% 2510.53%
Cash & Equivalents $47.23M $49.59M $49.60M
Short-Term Investments
Other Short-Term Assets $400.0K $19.00K $300.0K
YoY Change 100.0% -90.5% 50.0%
Inventory
Prepaid Expenses $304.0K
Receivables
Other Receivables
Total Short-Term Assets $47.67M $49.91M $49.90M
YoY Change 2169.95% 2201.24% 2168.18%
LONG-TERM ASSETS
Property, Plant & Equipment $182.0K $200.0K $200.0K
YoY Change 1438.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $182.0K $200.0K $200.0K
YoY Change 82.0% 1438.46%
TOTAL ASSETS
Total Short-Term Assets $47.67M $49.91M $49.90M
Total Long-Term Assets $182.0K $200.0K $200.0K
Total Assets $47.85M $50.11M $50.10M
YoY Change 2075.05% 2196.7% 2177.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $89.00K $193.0K $200.0K
YoY Change -11.0% 359.52%
Accrued Expenses $300.0K $400.0K $300.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $452.0K $640.0K $600.0K
YoY Change 352.0% 1388.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $452.0K $640.0K $600.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $452.0K $640.0K $600.0K
YoY Change -80.35% -66.19% -68.42%
SHAREHOLDERS EQUITY
Retained Earnings -$11.22M -$9.070M
YoY Change 688.7%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $47.40M $49.47M $49.50M
YoY Change
Total Liabilities & Shareholders Equity $47.85M $50.11M $50.10M
YoY Change 2075.05% 2196.7% 2177.27%

Cashflow Statement

Concept 2018 Q1 2017 Q4 2017
OPERATING ACTIVITIES
Net Income -$2.150M -$1.390M -$7.920M
YoY Change 335.22% 120.63% 588.7%
Depreciation, Depletion And Amortization $18.00K $10.00K $23.00K
YoY Change 1700.0% 1050.0%
Cash From Operating Activities -$2.369M -$2.130M -$3.890M
YoY Change 811.15% 147.67% 196.95%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$160.0K $210.0K
YoY Change -100.0% 1500.0% 1300.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$160.0K -$210.0K
YoY Change -100.0% 1500.0% 950.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.000K $42.47M
YoY Change 42369.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.000K -690.0K 51.77M
YoY Change -98.0% -128.75% 1492.92%
NET CHANGE
Cash From Operating Activities -2.369M -2.130M -3.890M
Cash From Investing Activities 0.000 -160.0K -210.0K
Cash From Financing Activities 6.000K -690.0K 51.77M
Net Change In Cash -2.363M -2.980M 47.67M
YoY Change -7976.67% -294.77% 2382.81%
FREE CASH FLOW
Cash From Operating Activities -$2.369M -$2.130M -$3.890M
Capital Expenditures $0.00 -$160.0K $210.0K
Free Cash Flow -$2.369M -$1.970M -$4.100M
YoY Change 787.27% 131.76% 209.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Trading Symbol
TradingSymbol
KRYS
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001711279
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49591000
CY2017 dei Entity Registrant Name
EntityRegistrantName
Krystal Biotech, Inc.
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10307247
CY2017Q2 dei Entity Public Float
EntityPublicFloat
0
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1923000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
304000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
193000
CY2017 dei Document Type
DocumentType
10-K
CY2017Q4 us-gaap Assets
Assets
50114000
CY2017Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
447000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
640000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
2169000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
49914000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
200000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-7920000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-1150000
CY2016Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
698000
CY2016Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1145000
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
246000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
19000
CY2016Q4 us-gaap Assets
Assets
2182000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
42000
CY2016Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
43000
CY2016Q4 krys Interest Payable Noncurrent
InterestPayableNoncurrent
7000
CY2017Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
0
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-4772000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-1143000
CY2017 krys Interest Income Expense And Other Nonoperating Net
InterestIncomeExpenseAndOtherNonoperatingNet
-3148000
CY2016 krys Interest Income Expense And Other Nonoperating Net
InterestIncomeExpenseAndOtherNonoperatingNet
-7000
CY2016Q4 us-gaap Common Unit Authorized
CommonUnitAuthorized
3490884
CY2017Q4 us-gaap Common Unit Issued
CommonUnitIssued
0
CY2016Q4 us-gaap Common Unit Issued
CommonUnitIssued
3490884
CY2017Q4 us-gaap Liabilities
Liabilities
640000
CY2016Q4 us-gaap Liabilities
Liabilities
1893000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2016Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2017Q4 us-gaap Common Unit Issuance Value
CommonUnitIssuanceValue
0
CY2016Q4 us-gaap Common Unit Issuance Value
CommonUnitIssuanceValue
0
CY2017Q4 us-gaap Limited Liability Company Llc Preferred Unit Issuance Value
LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue
0
CY2016Q4 us-gaap Limited Liability Company Llc Preferred Unit Issuance Value
LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue
1406000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
58544000
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
33000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9070000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1150000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
49474000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
289000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50114000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2182000
CY2017Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.00001
CY2016Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.00001
CY2017Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
20000000
CY2016Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2017Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
2061773
CY2016Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2017Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2016Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
0
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10307247
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
0
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10307247
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
0
CY2017Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2016Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2017Q4 us-gaap Common Unit Authorized
CommonUnitAuthorized
0
CY2017Q4 us-gaap Common Unit Outstanding
CommonUnitOutstanding
0
CY2016Q4 us-gaap Common Unit Outstanding
CommonUnitOutstanding
3490884
CY2017Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2016Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2017Q4 us-gaap Limited Liability Company Llc Preferred Unit Authorized
LimitedLiabilityCompanyLLCPreferredUnitAuthorized
0
CY2016Q4 us-gaap Limited Liability Company Llc Preferred Unit Authorized
LimitedLiabilityCompanyLLCPreferredUnitAuthorized
179613
CY2017Q4 us-gaap Limited Liability Company Llc Preferred Unit Issued
LimitedLiabilityCompanyLLCPreferredUnitIssued
0
CY2016Q4 us-gaap Limited Liability Company Llc Preferred Unit Issued
LimitedLiabilityCompanyLLCPreferredUnitIssued
179613
CY2017Q4 us-gaap Limited Liability Company Llc Preferred Unit Outstanding
LimitedLiabilityCompanyLLCPreferredUnitOutstanding
0
CY2016Q4 us-gaap Limited Liability Company Llc Preferred Unit Outstanding
LimitedLiabilityCompanyLLCPreferredUnitOutstanding
179613
CY2016Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
1406000
CY2017 us-gaap Operating Expenses
OperatingExpenses
4772000
CY2016 us-gaap Operating Expenses
OperatingExpenses
1143000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3148000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7920000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
33000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3208000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
741000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1564000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
402000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1150000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.48
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.31
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5360536
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
877490
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
100000
CY2016 krys Common And Preferred Units Issued During Period Value New Issues
CommonAndPreferredUnitsIssuedDuringPeriodValueNewIssues
1306000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
33000
CY2017 krys Temporary Equity Issued During Period Values Conversion Of Preferred Units To Preferred Stock
TemporaryEquityIssuedDuringPeriodValuesConversionOfPreferredUnitsToPreferredStock
-1406000
CY2017 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
3158000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
42446000
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
12661000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
246000
CY2017 us-gaap Depreciation
Depreciation
23000
CY2016 us-gaap Depreciation
Depreciation
2000
CY2017 us-gaap Paid In Kind Interest
PaidInKindInterest
3263000
CY2016 us-gaap Paid In Kind Interest
PaidInKindInterest
7000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
77000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
246000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
133000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
42000
CY2017 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
442000
CY2016 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3890000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1311000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
210000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-210000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-15000
CY2017 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1299000
CY2016 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1145000
CY2017 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1000000
CY2016 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
698000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
42469000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100000
CY2017 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
7000000
CY2016 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
1306000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
51768000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3249000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
47668000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1923000
CY2016 krys Conversion Of Common Units To Preferred Units
ConversionOfCommonUnitsToPreferredUnits
100000
CY2017 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
4142000
CY2017 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
12661000
CY2017 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
23000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.86%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, among others: stock-based compensation expense, accrued research and development expenses, the fair value of financial instruments, and the valuation allowance included in the deferred income taxes calculations.</p></div>
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.86%;">Financial instruments that potentially subject the Company to credit risk consist of cash. The Company&#8217;s policy is to invest its cash in money market funds and various bank deposit accounts. These financial instruments were held in Company accounts at two financial institutions. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</p></div>
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
54000
CY2017Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.22222222
CY2017 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
1-to-4.5
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2017Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
20000000
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017 krys Number Of Geographic Segment
NumberOfGeographicSegment
1
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017Q4 krys Recognized Income Tax Benefit
RecognizedIncomeTaxBenefit
0
CY2016Q4 krys Recognized Income Tax Benefit
RecognizedIncomeTaxBenefit
0
CY2017Q1 krys Stock Conversion Rate
StockConversionRate
1.0
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
185332
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
142105
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
225000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2000
CY2017Q4 krys Accrued Pre Clinical Expenses
AccruedPreClinicalExpenses
257000
CY2017Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
103000
CY2017Q4 krys Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
447000
CY2016Q4 krys Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1000
CY2017Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
0
CY2016Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1800000
CY2017Q4 krys Interest Payable Noncurrent
InterestPayableNoncurrent
0
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
102000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
0
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
0
CY2016Q2 us-gaap Preferred Units Authorized
PreferredUnitsAuthorized
100
CY2016Q2 us-gaap Preferred Units Issued
PreferredUnitsIssued
450
CY2016Q2 us-gaap Proceeds From Issuance Of Preferred Limited Partners Units
ProceedsFromIssuanceOfPreferredLimitedPartnersUnits
100000
CY2017Q4 krys Conversion Of Stock Conversion Price
ConversionOfStockConversionPrice
7.83
CY2017Q4 us-gaap Preferred Units Issued
PreferredUnitsIssued
96345
CY2017Q4 us-gaap Proceeds From Issuance Of Preferred Limited Partners Units
ProceedsFromIssuanceOfPreferredLimitedPartnersUnits
754000
CY2016Q4 us-gaap Preferred Units Issued
PreferredUnitsIssued
70497
CY2016Q4 us-gaap Proceeds From Issuance Of Preferred Limited Partners Units
ProceedsFromIssuanceOfPreferredLimitedPartnersUnits
552000
CY2017 us-gaap Conversion Of Stock Description
ConversionOfStockDescription
On March 31, 2017, all of the preferred units were converted into preferred stock on a 1-to-1 basis.
CY2017 krys Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
2.46
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
0
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
0
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
102000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals
OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
18000
CY2017Q4 krys Operating Leases Future Minimum Payments Due Net Of Sublease Rentals
OperatingLeasesFutureMinimumPaymentsDueNetOfSubleaseRentals
84000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
86000
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
450000
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
179613
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
179613
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45000000
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3490884
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3490884
CY2017Q3 krys Additional Common Stock Shares Authorized
AdditionalCommonStockSharesAuthorized
1500000
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2017Q3 krys Additional Preferred Stock Shares Authorized
AdditionalPreferredStockSharesAuthorized
1500000
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2017Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
4142000
CY2017Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
112000
CY2017Q3 us-gaap Long Term Debt
LongTermDebt
4254000
CY2017Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-3159000
CY2017 us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
The holders of shares of preferred stock are entitled to one vote for each share of preferred stock held
CY2017 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2017 us-gaap Common Stock Voting Rights
CommonStockVotingRights
The holders of shares of common stock are entitled to one vote for each share of common stock held
CY2017 us-gaap Dividends Common Stock Stock
DividendsCommonStockStock
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
71649
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
142105
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
142105
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
28422
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
185332
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
43221
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
43221
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.46
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.46
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.22
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
2.46
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.91
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.46
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.28
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2693000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2164000
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
1022000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-514000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
21000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 krys Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2
P9Y8M12D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y8M12D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2029000
CY2017Q4 krys Deferred Tax Assets Non Qualified Stock Options
DeferredTaxAssetsNonQualifiedStockOptions
29000
CY2017Q4 krys Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
-31000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
137000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2164000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2164000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017 krys Ownership Interest Rate Change Over Period
OwnershipInterestRateChangeOverPeriod
P3Y
CY2017 krys Tax Cuts And Jobs Act Of2017 Net Operating Loss Deduction Limitation Percent Of Taxable Income
TaxCutsAndJobsActOf2017NetOperatingLossDeductionLimitationPercentOfTaxableIncome
0.80
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y8M12D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M12D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
338000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1224000
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
348000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
348000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
246000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2016Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
0
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.28

Files In Submission

Name View Source Status
0001564590-18-005252-index-headers.html Edgar Link pending
0001564590-18-005252-index.html Edgar Link pending
0001564590-18-005252.txt Edgar Link pending
0001564590-18-005252-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201803121527011572339.jpg Edgar Link pending
g201803121527231211826.jpg Edgar Link pending
krys-10k_20171231.htm Edgar Link pending
krys-20171231.xml Edgar Link completed
krys-20171231.xsd Edgar Link pending
krys-20171231_cal.xml Edgar Link unprocessable
krys-20171231_def.xml Edgar Link unprocessable
krys-20171231_lab.xml Edgar Link unprocessable
krys-20171231_pre.xml Edgar Link unprocessable
krys-ex101_226.htm Edgar Link pending
krys-ex231_145.htm Edgar Link pending
krys-ex311_11.htm Edgar Link pending
krys-ex312_10.htm Edgar Link pending
krys-ex321_9.htm Edgar Link pending
krys-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending